Sun Pharma posted numbers better than expected on OPM and net profit front.
Sales came in at Rs7,764cr vs. Rs7,800cr expected vs. Rs6,858cr in 2QFY2016,
posting a yoy growth of 13.2%. On the operating front, the EBITDA margin came
in at 34.3% vs. 30.1% expected and vs. 27.1% in 2QFY2016. Lower expenses
during the quarter aided the OPM expansion. Consequently, the Adj. PAT came
in at Rs2,235cr vs. Rs1,545cr expected vs. Rs1,029cr in 2QFY2016, a yoy growth of
117.3%. Apart from better than expected OPM, the company also posted higher
than expected other income (Rs621cr in 2QFY2017 vs. Rs226cr in 2QFY2016). We
maintain our Buy rating on the stock.
View Full Report in Browser 
